Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10007053HBVENSG00000128052.10protein_codingKDRYesNo3791P35968
TVIS10007054HBVENSG00000128052.10protein_codingKDRYesNo3791P35968
TVIS10016656HBVENSG00000128052.10protein_codingKDRYesNo3791P35968
TVIS10000123HBVENSG00000128052.10protein_codingKDRYesNo3791P35968
TVIS20058066HPVENSG00000128052.10protein_codingKDRYesNo3791P35968
TVIS44025335HTLV-1ENSG00000128052.10protein_codingKDRYesNo3791P35968
TCGA Plot Options
Drug Information
GeneKDR
DrugBank IDDB08875
Drug NameCabozantinib
Target IDBE0000369
UniProt IDP35968
Regulation Typeantagonist
PubMed IDs21606412; 21926191
CitationsKurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.@@Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.
GroupsApproved; Investigational
Direct ClassificationDiarylethers
SMILESCOC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
Pathways
PharmGKB
ChEMBLCHEMBL2105717